<unk>  binds to the prefusion conformation of the RSV fusion protein, i.e. it binds to the site at which the virus would attach to a cell; effectively rendering it useless. It has a modified Fc region, extending the half-life of the drug in order for it to last the whole RSV season. Clinical efficacy The pivotal MELODY study is an ongoing, randomized, double-blind, placebo-controlled to evaluate the safety and efficacy of<unk>  in late preterm and term infants. Initial results have been promising, with<unk>  reducing LRTI (lower respiratory tract infections) by 74.5% compared to placebo in infants born at term or late preterm. Adverse effects No major hypersensitivity reactions have been reported, and adverse events of grade 3 or higher were only reported in 8% (77 of 968) of participants in clinical trial NCT02878330.
Nirsevimab
Atoltivimab
Regdanvimab
Odesivimab
Sotrovimab
Obiltoxaximab
Maftivimab
Bebtelovimab